Pfizer (PFE) Q2 2026 earnings review
Core Business Accelerates, but a $4.3B Write-Down Shatters R&D Narrative
Pfizer's Q2 tells a split-screen story. On one side, commercial execution is excellent: non-COVID revenue outperformed internal targets by $1.5B, driving an overall guidance raise. Launched and Acquired products grew an impressive 18% operationally. On the other side, capital allocation looks grim. A staggering $4.3B non-cash impairment charge—driven by a failed Phase 3 lung cancer trial and the market withdrawal of Oxbryta—pushed reported EPS into negative territory. While management celebrates a 'strong quarter,' the massive write-downs contradict the positive pipeline narrative and raise serious questions about past M&A diligence.
🐂 Bull Case
Excluding the collapsing COVID franchise, Pfizer's core portfolio grew 5% operationally. Management raised full-year non-COVID revenue expectations by $1.5B, proving the LOE (loss of exclusivity) bridge strategy is gaining traction.
Pfizer added another $2.5B to its cost savings target, bringing total expected savings to $6.7B from realignment and $3.0B from manufacturing by 2029. This is defending operating margins effectively.
🐻 Bear Case
The $4.3B intangible impairment is a glaring red flag. Writing off $3.8B for sigvotatug vedotin and $525M for Oxbryta highlights severe R&D missteps and obliterates reported profitability for the quarter.
Paxlovid revenues crashed 95% operationally. Management was forced to slash 2026 COVID guidance by another $1B to $4B. The floor for this franchise remains completely unpredictable.
⚖️ Verdict: ⚪
Neutral. The commercial execution on the newly acquired portfolio is genuinely strong, but a $4.3 billion write-down is too large to ignore. It erodes trust in management's R&D decision-making just as they ask investors to trust their new obesity and oncology pipeline.
Key Themes
Launched & Acquired Products Outperforming
This is the most critical growth driver for Pfizer. The basket of recently launched and acquired products grew 18% operationally YoY. Standouts include Padcev (+23% op) driven by first-line bladder cancer share gains, and Lorbrena (+37% op). This segment is successfully bearing the weight of legacy product declines.
Relentless Expense Reduction
Cost control is a primary mechanism for EPS defense. Pfizer announced an additional $2.5B in productivity savings from 2027-2029. Total targeted net savings now stand at $9.7B ($6.7B from cost realignment, $3.0B from manufacturing). SI&A expenses already contracted 1% YoY in Q2, validating the execution of these programs.
Eliquis Pricing Power in the U.S.
Eliquis delivered a massive 19% operational global growth quarter. Crucially, U.S. revenue surged 25%, driven not just by volume, but by higher net prices stemming from lower rebates and channel mix favorability. This demonstrates rare pricing resilience in an otherwise restrictive U.S. payer environment.
The $4.3 Billion R&D Blunder
Management frequently highlights a 'robust late-stage pipeline', but the data heavily contradicts this narrative. The company took a $3.8B write-down on sigvotatug vedotin after it failed to show statistically significant overall survival against docetaxel in Phase 3 NSCLC. Combined with a $525M impairment for Oxbryta's market unviability, this represents an enormous destruction of shareholder capital and casts a long shadow over the Seagen and Global Blood Therapeutics acquisitions.
COVID Franchise Contraction Accelerating
The COVID cliff has not yet found a bottom. Paxlovid collapsed 95% operationally to a mere $21M, while Comirnaty fell 34% to $261M. Management cut 2026 COVID revenue guidance by 20% (from $5.0B to $4.0B). This constant downward revision makes the top-line highly unpredictable.
Macro Pressure: Payer Contracting Squeezes Vyndaqel
While the Vyndaqel family grew 8% operationally globally, U.S. growth is decelerating due to macro headwinds. Management explicitly noted that continued market expansion in the U.S. was partially offset by net price erosion caused by aggressive new payer contracts. As the 2028 LOE approaches, margin compression here is a material risk.
Restocking the Oncology Shelf via Innovent
Perhaps reacting to the sigvotatug vedotin failure, Pfizer is aggressively pivoting to external innovation. The company closed a $650M upfront deal with Innovent Biologics to co-develop 12 new ADCs and bispecifics. This will dilute Q3 EPS by ~$0.10 but is a necessary step to maintain oncology momentum.
Other KPIs
Accelerating. R&D grew 12% operationally YoY. This outpaces total revenue growth (1%), creating near-term margin drag. Management attributes the spend to anticipated investments in oncology and obesity candidates. Investors must monitor whether this elevated spend generates actual ROI, given the recent $4.3B pipeline impairments.
Stable. Gross margins weakened slightly compared to the prior-year quarter (23.9%), driven by an unfavorable sales mix. However, the margin profile remains healthy and should benefit from the newly announced manufacturing cost optimization programs through 2029.
Guidance
Accelerating base business. The $500M midpoint raise ($61.5B) hides a much stronger underlying dynamic: non-COVID revenue expectations were raised by $1.5B, offsetting a $1.0B cut to COVID products. This proves the core commercial engine is firing on all cylinders.
Stable. Management reaffirmed this range despite the revenue raise. The top-line outperformance is being absorbed by higher R&D expenses and a $0.10 dilutive hit from the Innovent Biologics acquisition. Still, maintaining EPS while absorbing a $650M deal charge shows solid underlying operating leverage.
Key Questions
Seagen Pipeline Confidence
With the $3.8 billion write-down of sigvotatug vedotin failing to show an overall survival benefit in NSCLC, how does this alter your internal probability of success for the remaining Seagen ADC assets targeting solid tumors?
COVID Revenue Floor
You cut the 2026 COVID guidance from $5 billion down to $4 billion after Paxlovid dropped 95% this quarter. What specific metrics give you confidence that $4 billion is the final floor, rather than just another step down?
Vyndaqel Margin Compression
You cited net price erosion in the U.S. for Vyndaqel due to new payer contracts. Is this the beginning of a structural trend of margin compression ahead of the 2028 LOE, or a one-time contracting adjustment?
Innovent Deal Strategy
You just spent $650M upfront on 12 early-stage assets from Innovent. Was this deal accelerated specifically to plug the hole left by the sigvotatug vedotin failure, and how quickly can these enter pivotal trials?